Sitting at Work Tied to Higher Risk for Premature Death
24 Jan 2024
Clinical Result
WEDNESDAY, Jan. 24, 2024 -- Individuals who predominantly sit at work face a higher risk for all-cause and cardiovascular disease (CVD) mortality, according to a study published online Jan. 19 in JAMA Network Open.
Wayne Gao, Ph.D., from Taipei Medical University in Taiwan, and colleagues assessed whether health outcomes are associated with prolonged occupational sitting across various levels of physical activity in seemingly healthy adults. The analysis included 481,688 individuals followed for a mean 12.85 years.
The researchers found that when adjusting for sex, age, education, smoking, drinking, and body mass index, individuals who mostly sat at work had a higher all-cause mortality risk (hazard ratio [HR], 1.16; 95 percent confidence interval [CI], 1.11 to 1.20) and CVD-related mortality risk (HR, 1.34; 95 percent CI, 1.22 to 1.46) compared with those who were mostly nonsitting at work. There was no increased risk for all-cause mortality among individuals alternating sitting and nonsitting at work (HR, 1.01; 95 percent CI, 0.97 to 1.05). Participants with a personal activity intelligence score >100 experienced a reduction in the elevated mortality risk associated with prolonged occupational sitting. An increase in leisure-time physical activity (LTPA) by 15 and 30 minutes per day, respectively, for individuals mostly sitting at work and engaging in low (15 to 29 minutes per day) or no (
"Emphasizing the associated harms and suggesting workplace system changes may help society to denormalize this common behavior, similar to the process of denormalizing smoking," the authors write.
Abstract/Full Text
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Posted January 2024
More news resources
FDA Medwatch Drug Alerts
Daily MedNews
News for Health Professionals
New Drug Approvals
New Drug Applications
Drug Shortages
Clinical Trial Results
Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.